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Identification of novel targets in cancer immunotherapy
is needed to address the significant number of patients
that either do not respond to current therapies or
encounter unacceptable toxicities. The discovery of such
targets, including novel checkpoint regulators and the
counter-receptors for previously “orphan” checkpoints,
has been limited by a lack of a comprehensive collection
of proteins suitable for functional screening and methods
for assessing their function in high-throughput.
We have generated a comprehensive library of substan-
tially all human extracellular proteins encompassing nearly
every target for protein therapeutics. Our library contains
more than 5700 proteins, including secreted protein
ligands and the extracellular domains of membrane-bound
receptors in soluble forms. In addition, we have developed
in vitro and in vivo high-throughput protein screening
platforms for discovering and validating new targets in a
variety of disease areas. Our discovery platforms are
uniquely suited for the discovery of novel targets in cancer
immunotherapy. Based on domain structure, phylogeny
and other factors, we identified a subset of 391 human
proteins in our library that are enriched for possible cell
surface-expressed immune regulatory proteins. These
proteins were screened for the ability to modulate anti-
CD3-stimulated human T cell proliferation. This screen
identified a number of known checkpoint regulators,
which validates the discovery platform and screening
approach. In addition, we identified numerous novel
co-inhibitory proteins - the majority of which have no
published link to immune cell regulation. For a number
of these proteins, we have demonstrated co-inhibitory
activity in orthogonal assays, such as assays of cytokine
production from purified T cell subpopulations and in
mixed lymphocyte reaction assays. Further in vitro and in
vivo characterization of these proteins is ongoing. These
data demonstrate the power of our screening platform to
discover potentially new therapeutic targets for cancer
immunotherapy.
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